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Introduction
Allogeneic hematopoetic stem cell transplantation is a potentially curative procedure for myeloma. It is associated with lower relapse rates compared to autologous transplantation and some patients become long term disease free survivors [1] [2] [3] [4] . The use of allogeneic transplantation has however remained restricted to a sub-population of patients, as most are older than the conventionally accepted age limits for transplant and/or lack a suitable donor.
In addition the high TRM of up to 44% has deterred both patients and their physicians 4, 5 .
More recently a reduction in TRM from 38% to 21% has been noted for patients transplanted between 1983-1993 and 1994-1998 6 , respectively. This improvement can be attributed at least in part to better patient selection and in part to improvements in supportive care.
However with the upper age of these patients being less than 60 years it is clear that conventional allogeneic transplantation, even with the best results, remains applicable only to a minority of patients with myeloma.
The introduction of reduced intensity conditioning regimens for transplant (RICT), with a reduction in immediate transplant related mortality [7] [8] [9] has renewed interest in allogeneic transplant for myeloma. In the context of RICT, the use of in vivo T cell depletion with AntiThymocyte Globulin (ATG) or alemtuzumab (Campath-1H) have been associated with a very low incidence of graft versus host disease 10 and consequently RICT have become the More recent studies have reported better outcomes using either fludarabine and melphalan as the conditioning chemotherapy or tandem autograft and allograft approaches with event free survivals at 2 years of 33% and 56%, respectively [13] [14] [15] . Similar results have been observed by the Seattle group 16 using fludarabine and low dose TBI. Overall the published experience in myeloma remains small. The purpose of the present study was to establish evidence of efficacy and to identify clinically important prognostic factors.
Patients and Methods
This study was conducted on behalf of the Chronic Leukaemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT) and was performed in conjunction with a study of reduced intensity conditioning transplantation in chronic myeloid leukemia. All EBMT centers report a minimal essential dataset into a central database. All centers that had reported more than 5 RICT for myeloma and/or CML were asked for additional data. This analysis is restricted to those patients with myeloma. Informed consent was obtained locally according to the regulations applicable at the time of transplant. Since 1st Jan 2003 the EBMT has required centres to confirm that written informed consent has been obtained prior to data acceptance. The definition of RICT was determined by contributing centers and was based on the current EBMT guidance. Patients who received regimens with equivalent to or lower intensity than melphalan 140mg/m 2 were included in the study. Patients who had received TBI were included provided the delivered dose was 6 Gy.
The minimum dataset required for inclusion of a patient in the study was defined at the 
Definitions
The diagnosis of myeloma was based on local review. Chemosensitive disease was defined as all patients who were in complete remission (CR) or partial response (PR) following the last course of chemotherapy prior to transplant. Chemoresistance was defined as patients who had had no or minimal response or disease progression. Response, relapse and disease progression were defined according to published criteria 17 . Response was documented on or after day 100 post transplant. Survival was measured in months and defined as the time from the date of transplant until date of death or last follow up.
Progression free survival was defined as the time from transplant until date of progression/death from any cause or last follow up. Treatment related mortality was defined as death due to any cause other than disease progression or relapse occurring at any time after transplant. Landmark analyses were performed for chronic graft versus host disease (cGvHD) where only patients surviving more than 100 days were included.
Statistical analysis
Probabilities of OS and PFS were calculated using the method of Kaplan-Meier, whilst probabilities of transplant related mortality and relapse were estimated using the cumulative incidence procedure. Univariate comparisons were made using the log-rank test and variables found to be significant at the P< 0.2 level were entered into a proportional hazards regression analysis using a backward stepping procedure. Comparisons between groups were made using the Chi-squared test for categorical data, and the Mann-Whitney test for continuous data. All quoted p-values are from two-sided tests, and values of <0.05 were considered significant. Quoted confidence intervals (CI) refer to 95% boundaries.
Results
Data from 268 patients transplanted between June 1998 and Feb 2003 were collected from from 36 centers within the EBMT group. The minimum essential dataset was available for 229 patients from 33 centers and these patients form the basis for this study.
Patient characteristics
The median age of the cohort was 52 years (range 32-66) and 147 were male. The median time from diagnosis to transplant was 1.6 yrs (2.0 months to 11 yrs). Fifty eight percent, 21% 
Conditioning and transplant details
A number of different reduced intensity conditioning regimens were used and are listed in Table 2 . The majority were fludarabine based (96%) with the addition of either busulphan or melphalan. Seventy-nine patients received ATG as in vivo T cell depletion and 55 patients received alemtuzumab, most frequently in combination with fludarabine and melphalan.
Peripheral blood was used as the source of cells in 183 patients and bone marrow in 46.
Median cell doses for peripheral blood were 5.27 x10 6 CD34/kg and for marrow 2.92 x10 8 MNC/kg. GvHD prophylaxis consisted of cyclosporin alone (56%), cyclosporin and methotrexate (30%), cyclosporin and steroid (2%), methotrexate alone (3%) and was unknown in 9%.
Engraftment and Chimerism
Engraftment occurred in 94% regardless of the source of stem cells with an additional 1% subsequently losing the graft. The median times to neutrophil (>0.5 x10 9 /l) and platelet recovery (>50 x10 9 /l) were 14 days (0-393) and 14 days (0-374), respectively. There was a significant difference between patients receiving peripheral blood stem cells (PBSC) and marrow in the time to neutrophil recovery (13 vs 16 days p=0.001) and to platelet recovery (13 vs 22 days p<0.001). All patients receiving marrow became neutropenic and only one did not become thrombocytopenic whereas 10% of those receiving PBSC had a neutrophil count > 0.5 x10 9 /l at all times and 13 % did not become thrombocytopenic (>50 x10 9 /l). Chimerism data were available on 190 patients. At best 81% achieved full donor chimerism and 86%
were greater than 95% donor. On subsequent analysis this had fallen to 74% full donor and to 80% greater than 95% donor.
Graft vs Host Disease
Acute GvHD occurred in 100 patients (44%) with 29 (13%) experiencing grade I and 72 (31%) grade II-IV disease. The incidence of aGvHD was not significantly altered by the use of ATG or alemtuzumab in the conditioning, the use of peripheral blood versus marrow or GvHD prophylaxis. Grade III-IV aGvHD was associated with inferior survival (43% vs 21% at 3yrs, p=0.0007) but did not alter the incidence of relapse. 174 patients were evaluable for cGvHD of whom 44 (25%) developed limited and 43 (25%) extensive cGvHD. The use of T cell depleting antibodies significantly reduced the incidence of cGvHD (71% vs 39%,
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From p<0.001) and this reduction was greater in patients receiving alemtuzumab than ATG (32% vs 41%). The use of peripheral blood was associated with an increased incidence of cGvHD (55% vs 31% p=0.01) unlike the donor recipient gender combination which was not significantly linked with GvHD.
Transplant related mortality
Sixty patients died of procedural related complications, of whom 26 died before day 100. The causes of death were GvHD (n=11), infection (n=39), pneumonitis (n=4), hemorrhage (n=4), cardiac toxicity (n=2), graft failure (n=2) lymphoproliferative disorder (n=1) and other malignancies (n=2). In several patients the cause of death was multifactorial. In patients receiving alemtuzumab 16/31 deaths were secondary to infection. The treatment related mortalities at day 100, 1 year and 2 years were 10%, 22% and 26%, respectively. Factors on univariate analysis associated with a higher transplant related mortality (TRM) were female donors to male recipients (37% vs 16% 1 year TRM p=0.0004, Table 3 ), transplant more than one year from diagnosis (30% vs 15% p=0.004) and the use of an unrelated donor (40% vs 20% p=0.03). Of these a female to male donation and disease duration greater than one year retained significance on multivariate analysis (Table 4) . Overall the TRM is less than 20% in patients with none or one of these risk factors
Response post transplant
Overall 25% (58/229) and 48% (110/229) of patients attained CR and PR, respectively. The disease was stable in 12% (28/229) and 7% (15/229) had progressive disease. 8% (18/229) were not evaluable due to treatment related deaths. Of the patients (10%) in CR prior to the transplant 87% remained in CR. Of the patients transplanted in PR, 20% (24) attained a CR post transplant, 66% (81) remained in PR and 7% (8) had progressive disease. In patients with progressive disease at transplant,18% (11) and 27% (17) achieved CR and PR, respectively, and in 34% (21) their disease stabilized. Only five patients in this group had early disease progression (Table 5 ). Response assessment was at or after 100 days post transplant..
Survival
With a median follow up of 28 months, 115 patients are alive (1-53 months) . The estimated overall survival at 3 years is 40.6% (CI 33-49%) (Figure 1 ). On univariate analysis (Table 3) a CR or PR prior to transplant was associated with with an improved overall survival (p=0.0006) with patients in first remission having the best outcomes (p=0.0001). One prior autograft did not confer an adverse prognosis compared with no prior autograft, 3 year survivals of 46%% and 41%, respectively. Patients receiving more than one prior autograft For personal use only. on August 31, 2017. by guest www.bloodjournal.org From had an inferior survival of 23% at 3 years (p=0.003). Disease duration of less than one year (p=0.002), and the use of a related vs unrelated donor (p=0.002) and gender combinations other than male patients with female donors (p=0.03) were also associated with better survival. The use of busulphan in conditioning was associated with inferior survival (p=0.01).
Factors which retained significance on multivariate analysis were: transplant in first remission, and less than two prior autografts (Table 4) patients have died from disease. The cumulative probability of progression was 50% and the progression free survival was 21.3% (CI 15-29%) at 3 years. The following factors were associated with an adverse progression free survival on univariate analysis (Table 3) , chemoresistance (p=0.0002), patients in >1 st remission (p=0.0007), two or more prior autografts (p=0.02), the use of an unrelated donor (p=0.02) and the use of alemtuzumab in the conditioning (p=0.004). Chemoresistant disease, and the use of alemtuzumab retained significance on multivariate analysis (Table 4) .
Of the post transplant variables the development of any cGvHD was associated with better overall and progression free survivals (p<0.0001 Figure 2 ). Overall survival was best in those patients with limited disease, 84% at 3yrs vs 58% for extensive and 29% in the absence of cGvHD (Figure 2) . PFS was likewise better in patients with limited disease 46% compared to 30% for extensive cGvHD and 12% without cGvHD. An increase in TRM associated with extensive cGvHD did not reach significance. For aGvHD no effect on overall survival or progression free survival could be demonstrated for either the presence or severity of disease although grade III-IV aGvHD was associated with an increased TRM.
Donor Lymphocyte Infusions (DLI)
Eighty patients received a median number of 2 donor lymphocyte infusions (range 1-6) with the final cell dose infused being a median of 1 x10 7 CD3/kg (range 1x10 
Discussion
Reduced intensity conditioning transplants are clearly feasible in many patients with myeloma. The sustained engraftment rate at 93% was similar to that seen with conventional allogeneic transplant and is comparable to data from single and multi-center studies [12] [13] [14] 16, 18 .
The majority of patients achieved full donor chimerism at approximately 3 months post transplant and secondary graft failure was infrequent.
The primary motivation for the development of reduced intensity conditioning has been to decrease the TRM. As the TRM in conventional allografts increases with the ages of both the donor and recipient 19,20 a secondary aim of RICT is to extend the age range of patients that might benefit from more aggressive therapy. This is particularly important in a malignancy such as myeloma where the median age at onset is in the seventh decade. In our study early TRM at day 100 was low at 10% but it is important to recognize the continuing attrition rate with the TRM rising to 26% at 2 years. Consistent with this is the observation that many complications of allogeneic transplant such as GvHD are being delayed by RICT rather than being prevented
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. The low TRM was also not universal and male patients with a female donor who were transplanted more than one year from diagnosis had a TRM of 52% at 1 year. A similarly high risk was seen in other studies of heavily pretreated patients 12, 18 . In contrast to conventional allografts age was not found to be an important factor in predicting outcome. 
The profound T cell depletion induced by alemtuzumab is likely to be contributing to this late
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 2/3/2005 mortality. The incidence of grade III-IV aGvHD was the same in the alemtuzumab and ATG groups but the incidence of cGvHD was lower in the alemtuzumab group. This difference was not marked (40% vs 32%). CD52 expression is not limited however to T cells and depletion other cellular targets of alemtuzumab such as NK cells or host dendritic cells may be important in contributing to the adverse effect on progression free survival seen 22, 23 .
The rationale for allogeneic transplant is firstly the ability to deliver high dose chemotherapy supported by hematopoietic progenitor cells that are free of tumor contamination and secondly the harnessing of an immune anti-tumour effect. The efficacy of RICT is dependent primarily on the latter effect. The improvement in progression free and overall survival associated with the development of cGvHD has been reported 24, 25 and supports the existence of a graft versus myeloma (GvM) effect, as do the responses seen with donor lymphocyte infusions. There is nothing in these data however to support the existence of a specific GvM immune effect as opposed to a more non-specific allogeneic response. At present there is no evidence of long term disease control with a continued fall off in the PFS being seen even in those patients with cGvHD. Whilst it may be premature to exclude a plateau to the survival curves in the majority of patients the disease progresses despite transplantation. Furthermore whilst there may be an important GvM effect in a minority of patients given the importance of disease remission status at the time of transplant it would appear that it is insufficiently potent to overcome bulk or progressive disease.
Data on the extent of prior treatment is limited although surrogate markers such as prior high dose therapy and time from diagnosis to transplant are associated with adverse outcomes.
The latter did not retain significance in multivariate analysis. Consistent with recent data 26 there did not appear to be an adverse outcome associated with one prior autograft when this was done as part of a planned two-stage procedure or as a separate therapy. Several ongoing studies both in Europe and North America are utilizing autologous transplant as cytoreductive therapy prior to a RICT. These data would suggest that this approach is unlikely to be detrimental Male gender and mis-match between donor and recipient gender are well recognized but not universal risk factors for a a higher treatment related mortality in allogeneic transplantation 6, 27 . Male patients in this series had an inferior survival which was largely explained by those male patients with female donors who had significantly adverse outcomes with respect to survival and treatment related mortality. This study begins to identify clinical factors that will help with patient selection. Reserving this treatment for patients in whom other therapies have failed is unlikely to result in beneficial outcomes. The best outcomes were seen in patients transplanted in remission and earlier in the course of the disease. This study suggests that gender is an important factor in donor selection and that the use of alemtuzumab may be detrimental. The effect of cGvHD on OS and PFS is suggestive of a GvM effect although whether this can be separated from a non-specific alloimmune effect is uncertain. Blood. 2001; 98:2043 -2051 20. Klingemann HG, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986 67:770-776 21. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus- host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003; 102:756-762 22. Ratzinger G, Reagan J, Heller G, et al. Differential CD52 expression by distinct myeloid dendritic cell subsets:implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003; 101:1422 -1429 versus-tumor activity. Biol Blood Marrow Transplant. 2003; 9:257-265 24. Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001; 115:653-659 25. Einsele H, Schafer HJ, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol. 2003; 121:411-418 26. Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization as prognostic factor following allogeneic dose-reduced stem cell transplantation in patients with multiple myeloma. Blood. 2004 :2003 -2012 -4435 27. Randolph SSB, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004 103:347-352 (12) 15 (7) 18 (8) 229 Relapse Probability For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
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